Literature DB >> 28114597

Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome.

Maria Nirvana da Cruz Formiga1, Kelvin César de Andrade2, Luiz Paulo Kowalski3, Maria Isabel Achatz4.   

Abstract

IMPORTANCE: Li Fraumeni syndrome (LFS) is associated with a wide variety of tumors; nevertheless, thyroid carcinoma has not been evaluated in this syndrome. Due to the Brazilian founder mutation p.R337H, some tumors that have not been described in the classic LFS have been observed in a higher-than-expected prevalence in Brazil.
OBJECTIVE: To determine the frequency of thyroid carcinoma in Brazilian carriers of a founder TP53 p.R337H mutation. DESIGN, SETTING, AND PARTICIPANTS: We reviewed medical records of patients with LFS with germline TP53 p.R337H mutation. For a better understanding of the correlation between thyroid carcinoma and LFS, tumor profile data of Brazilian carriers were analyzed. We included data from 193 patients with LFS with the TP53 p.R337H mutation from the database of the Department of Oncogenetics from the A.C. Camargo Cancer Center. MAIN OUTCOMES AND MEASURES: Thyroid tumors found in this population were reviewed with regard to age at diagnosis, sex, histologic subtype, and other tumors presented by these patients.
RESULTS: Overall, 101 of 193 TP53 p.R337H mutation carriers with LFS from 58 families were cancer affected and, among them, thyroid carcinoma presented a prevalence of 10.9% (3 men and 8 women). The mean age at diagnosis was 44 years (median [SD], 43 [14.77] years). All the cases were histologically classified as papillary carcinomas, with 2 of them exhibiting follicular variant. The most common other cancers in the patients with thyroid carcinoma were breast cancer (5 patients) and soft-tissue sarcoma (2 patients). CONCLUSIONS AND RELEVANCE: Thyroid carcinoma may be associated with the Brazilian founder TP53 p.R337H mutation. Knowledge about this genotype/phenotype correlation is relevant to adjusting the LFS screening recommendations to these specific carriers.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28114597      PMCID: PMC5824314          DOI: 10.1001/jamaoncol.2016.6389

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  8 in total

1.  [Papillary thyroid carcinoma in Li-Fraumeni syndrome: Sporadic case or a rare association?].

Authors:  Emilio Peña Ros; Maria Fe Candel Arenas; Antonio Albarracín Marín-Blázquez
Journal:  Med Clin (Barc)       Date:  2016-05-18       Impact factor: 1.725

2.  Li-fraumeni syndrome.

Authors:  David Malkin
Journal:  Genes Cancer       Date:  2011-04

3.  Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.

Authors:  Gaëlle Bougeard; Mariette Renaux-Petel; Jean-Michel Flaman; Camille Charbonnier; Pierre Fermey; Muriel Belotti; Marion Gauthier-Villars; Dominique Stoppa-Lyonnet; Emilie Consolino; Laurence Brugières; Olivier Caron; Patrick R Benusiglio; Brigitte Bressac-de Paillerets; Valérie Bonadona; Catherine Bonaïti-Pellié; Julie Tinat; Stéphanie Baert-Desurmont; Thierry Frebourg
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

4.  F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.

Authors:  Serena Masciari; Annick D Van den Abbeele; Lisa R Diller; Iryna Rastarhuyeva; Jeffrey Yap; Katherine Schneider; Lisa Digianni; Frederick P Li; Joseph F Fraumeni; Sapna Syngal; Judy E Garber
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

5.  The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.

Authors:  Maria Isabel Waddington Achatz; Magali Olivier; Florence Le Calvez; Ghyslaine Martel-Planche; Ademar Lopes; Benedito Mauro Rossi; Patricia Ashton-Prolla; Roberto Giugliani; Edenir Inez Palmero; Fernando Regla Vargas; José Claudio Casali Da Rocha; Andre Luiz Vettore; Pierre Hainaut
Journal:  Cancer Lett       Date:  2006-02-21       Impact factor: 8.679

6.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

Review 7.  Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.

Authors:  Junne Kamihara; Huma Q Rana; Judy E Garber
Journal:  Hum Mutat       Date:  2014-06       Impact factor: 4.878

Review 8.  The concise handbook of family cancer syndromes. Mayo Familial Cancer Program.

Authors:  N M Lindor; M H Greene
Journal:  J Natl Cancer Inst       Date:  1998-07-15       Impact factor: 13.506

  8 in total
  8 in total

1.  The TP53 p.R337H mutation is uncommon in a Brazilian cohort of pediatric patients diagnosed with ependymoma.

Authors:  Taciani de Almeida Magalhães; Kleiton Silva Borges; Graziella Ribeiro de Sousa; Silvia Regina Brandalise; Ana Luiza Seidinger; Carlos Alberto Scrideli; Sueli Mieko Oba-Shinjo; José Andrés Yunes; Luiz Gonzaga Tone
Journal:  Neurol Sci       Date:  2019-11-14       Impact factor: 3.307

Review 2.  Genetic susceptibility to hereditary non-medullary thyroid cancer.

Authors:  Tina Kamani; Parsa Charkhchi; Afshan Zahedi; Mohammad R Akbari
Journal:  Hered Cancer Clin Pract       Date:  2022-03-07       Impact factor: 2.857

Review 3.  The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?

Authors:  Margaret Ottaviano; Emilio Francesco Giunta; Pasquale Rescigno; Ricardo Pereira Mestre; Laura Marandino; Marianna Tortora; Vittorio Riccio; Sara Parola; Milena Casula; Panagiotis Paliogiannis; Antonio Cossu; Ursula Maria Vogl; Davide Bosso; Mario Rosanova; Brunello Mazzola; Bruno Daniele; Giuseppe Palmieri; Giovannella Palmieri
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

4.  XAF1 as a modifier of p53 function and cancer susceptibility.

Authors:  Emilia M Pinto; Bonald C Figueiredo; Wenan Chen; Henrique C R Galvao; Maria Nirvana Formiga; Maria Candida B V Fragoso; Patricia Ashton-Prolla; Enilze M S F Ribeiro; Gabriela Felix; Tatiana E B Costa; Sharon A Savage; Meredith Yeager; Edenir I Palmero; Sahlua Volc; Hector Salvador; Jose Luis Fuster-Soler; Cinzia Lavarino; Guillermo Chantada; Dominique Vaur; Vicente Odone-Filho; Laurence Brugières; Tobias Else; Elena M Stoffel; Kara N Maxwell; Maria Isabel Achatz; Luis Kowalski; Kelvin C de Andrade; Alberto Pappo; Eric Letouze; Ana Claudia Latronico; Berenice B Mendonca; Madson Q Almeida; Vania B Brondani; Camila M Bittar; Emerson W S Soares; Carolina Mathias; Cintia R N Ramos; Moara Machado; Weiyin Zhou; Kristine Jones; Aurelie Vogt; Payal P Klincha; Karina M Santiago; Heloisa Komechen; Mariana M Paraizo; Ivy Z S Parise; Kayla V Hamilton; Jinling Wang; Evadnie Rampersaud; Michael R Clay; Andrew J Murphy; Enzo Lalli; Kim E Nichols; Raul C Ribeiro; Carlos Rodriguez-Galindo; Marta Korbonits; Jinghui Zhang; Mark G Thomas; Jon P Connelly; Shondra Pruett-Miller; Yoan Diekmann; Geoffrey Neale; Gang Wu; Gerard P Zambetti
Journal:  Sci Adv       Date:  2020-06-24       Impact factor: 14.957

5.  A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma.

Authors:  Xian Wang; Shan Huang; Xiaocan Li; Dongrui Jiang; Hongzhen Yu; Qiang Wu; Chaobing Gao; Zhengsheng Wu
Journal:  PLoS One       Date:  2018-07-13       Impact factor: 3.240

Review 6.  Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.

Authors:  Fabíola Yukiko Miasaki; Cesar Seigi Fuziwara; Gisah Amaral de Carvalho; Edna Teruko Kimura
Journal:  Genes (Basel)       Date:  2020-11-18       Impact factor: 4.096

7.  Frequency of the TP53 R337H variant in sporadic breast cancer and its impact on genomic instability.

Authors:  Carolina Mathias; Stéfanne Bortoletto; Ariana Centa; Heloisa Komechen; Rubens S Lima; Aline S Fonseca; Ana Paula Sebastião; Cícero A Urban; Emerson W S Soares; Carolina Prando; Bonald C Figueiredo; Iglenir J Cavalli; Luciane R Cavalli; Enilze M F S Ribeiro
Journal:  Sci Rep       Date:  2020-10-06       Impact factor: 4.379

Review 8.  What 20 years of research has taught us about the TP53 p.R337H mutation.

Authors:  Emilia Modolo Pinto; Gerard P Zambetti
Journal:  Cancer       Date:  2020-08-17       Impact factor: 6.860

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.